Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG).

Full DD Report for EYEG

You must become a subscriber to view this report.


Recent News from (NASDAQ: EYEG)

EyeGate's EGP-437 flunks late-stage study in eye inflammation; shares down 25%
Nano cap EyeGate Pharmaceuticals ( EYEG -24.7% ) is down on triple normal volume on the heels of its announcement that a Phase 3 clinical trial evaluating EGP-437 (dexamethasone phosphate ophthalmic solution), delivered through the EyeGate II Drug Delivery System, failed to demonstrate...
Source: SeekingAlpha
Date: September, 04 2018 12:43
EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies
WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the first three patients ha...
Source: GlobeNewswire
Date: September, 04 2018 08:31
EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis
WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced top-line results from its Phase 3 stu...
Source: GlobeNewswire
Date: September, 04 2018 08:30
EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference
WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the Company will present at the u...
Source: GlobeNewswire
Date: August, 29 2018 08:30
Enrollment underway in EyeGate Pharma's pilot study of OBG in patients following PRK surgery
The first participant has been enrolled in EyeGate Pharmaceuticals' ( EYEG -2.2% ) Phase 1/2 clinical trial assessing its Ocular Bandage Gel (OBG) to accelerate re-epithelialization of large corneal epithelial defects in patients who have undergone photorefractive keratectomy (PRK) sur...
Source: SeekingAlpha
Date: August, 20 2018 09:46
EyeGate Announces Enrollment of First Patient in PRK Pilot Study
WALTHAM, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the first patient has been enroll...
Source: GlobeNewswire
Date: August, 20 2018 08:30
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf
WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the e...
Source: GlobeNewswire
Date: August, 07 2018 08:30
Eyegate Pharmaceuticals reports Q2 results
Eyegate Pharmaceuticals (NASDAQ: EYEG ): Q2 Net loss of $2.78M More news on: EyeGate Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 03 2018 08:47
EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
WALTHAM, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the e...
Source: GlobeNewswire
Date: August, 03 2018 08:30
Your Daily Pharma Scoop: Biohaven In Pivotal Stage, Merck Trial Positive, FDA Waives EyeGate
Biohaven launches Phase 2/3 study of trigriluzole in Alzheimer's Discussion : Biohaven Pharmaceutical Holding Company ( BHVN ) commences Phase 2/3 trial of its candidate BHV-4157 (trigriluzole) in patients with mild-to-moderate Alzheimer's disease (‘AD). Patient enrollment is expec...
Source: SeekingAlpha
Date: July, 27 2018 03:48

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-120.400.51750.550.401,561,603
2018-12-110.4260.410.4280.40105,786
2018-12-100.410.400.4540.38515,445
2018-12-070.480.42020.480.40412,319
2018-12-060.500.46730.500.46186,727

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-12376,092517,82572.6292Short
2018-12-1113,63846,06829.6041Cover
2018-12-1015,39969,09922.2854Cover
2018-12-0738,42799,81638.4978Short
2018-12-061,63771,0772.3031Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EYEG.


About Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG)

Logo for Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG)

EyeGate is a clinical stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP , the company s first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through EyeGate s proprietary innovative drug delivery system, the EyeGate II Delivery System. For more information, please visit www.EyeGatePharma.com.

 

Contact Information

 

 

Current Management

  • Stephen From / CEO, CFO
  • Michael Manzo / VP, Eng.
  • Paul Chaney / Chairman
  • Thomas Balland /
  • Mounia Chaoui /
  • Stephen From /
  • Morton Goldberg /
  • Thomas E. Hancock /
  • Bernard MalfroyCamine /
  • Praveen Tyle /

Current Share Structure

  • Market Cap: $26,093,547 - 05/16/2018
  • Authorized: 100,000,000 - 05/01/2018
  • Issue and Outstanding: 41,411,755 - 05/01/2018

 


Recent Filings from (NASDAQ: EYEG)

Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: May, 17 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: April, 23 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 23 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 18 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 17 2018
Prospectus filed under Rule 424(b)(4)
Filing Type: 424B4Filing Source: edgar
Filing Date: April, 16 2018

 

 


Daily Technical Chart for (NASDAQ: EYEG)

Daily Technical Chart for (NASDAQ: EYEG)


Stay tuned for daily updates and more on (NASDAQ: EYEG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: EYEG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EYEG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EYEG and does not buy, sell, or trade any shares of EYEG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/